Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant pembrolizumab + cisplatin + paclitaxel in locally advanced head and neck squamous cell carcinoma
ChiCTR2400091507Phase 2Recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Liaoning Province Cancer Hospital. Primary endpoints: Pathologic complete response rate of primary tumor (pCR) and 2-year progression-free survival in Arm1 (2y-PFS). Started Oct 2024; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2400091507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091507.